CN103702994A - 旋转酶和拓扑异构酶抑制剂的磷酸酯 - Google Patents
旋转酶和拓扑异构酶抑制剂的磷酸酯 Download PDFInfo
- Publication number
- CN103702994A CN103702994A CN201280036458.1A CN201280036458A CN103702994A CN 103702994 A CN103702994 A CN 103702994A CN 201280036458 A CN201280036458 A CN 201280036458A CN 103702994 A CN103702994 A CN 103702994A
- Authority
- CN
- China
- Prior art keywords
- compound
- infection
- ethyl
- resistance
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QWTBDIBOOIAZEF-UHFFFAOYSA-N CC(C)N(C(C)C)P(OCCC#N)Cl Chemical compound CC(C)N(C(C)C)P(OCCC#N)Cl QWTBDIBOOIAZEF-UHFFFAOYSA-N 0.000 description 1
- FJFAEKLCNIXADS-UHFFFAOYSA-N CC(C)N(C(C)C)P(OCCC#N)OCCOCCOC Chemical compound CC(C)N(C(C)C)P(OCCC#N)OCCOCCOC FJFAEKLCNIXADS-UHFFFAOYSA-N 0.000 description 1
- 0 CCNC(Nc1nc(cc(-c2cnc(C(C)(C)O*)nc2)c(F)c2[C@@]3OCCC3)c2[n]1)=O Chemical compound CCNC(Nc1nc(cc(-c2cnc(C(C)(C)O*)nc2)c(F)c2[C@@]3OCCC3)c2[n]1)=O 0.000 description 1
- FVJUSVJRVMFHIF-GQLFNYOGSA-N CCNC(Nc1nc(cc(C2C#CN=C(C(C)(C)OP(OCCC#N)(OCCOCCOC)=O)N=C2)c(F)c2[C@@H]3OCCC3)c2[nH]1)=O Chemical compound CCNC(Nc1nc(cc(C2C#CN=C(C(C)(C)OP(OCCC#N)(OCCOCCOC)=O)N=C2)c(F)c2[C@@H]3OCCC3)c2[nH]1)=O FVJUSVJRVMFHIF-GQLFNYOGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
选择的化合物 | Ki(nM) |
化合物23 | 9 |
化合物X | <9 |
化合物Y | 13 |
化合物Z | <9 |
选择的化合物 | Ki(nM) |
化合物23 | 9 |
化合物X | 45 |
化合物Y | 24 |
化合物Z | 80 |
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161499144P | 2011-06-20 | 2011-06-20 | |
US61/499,144 | 2011-06-20 | ||
PCT/US2012/043266 WO2012177707A1 (en) | 2011-06-20 | 2012-06-20 | Phosphate esters of gyrase and topoisomerase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103702994A true CN103702994A (zh) | 2014-04-02 |
CN103702994B CN103702994B (zh) | 2016-03-23 |
Family
ID=46457069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280036458.1A Active CN103702994B (zh) | 2011-06-20 | 2012-06-20 | 旋转酶和拓扑异构酶抑制剂的磷酸酯 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9125922B2 (zh) |
EP (1) | EP2721026B1 (zh) |
JP (1) | JP5977344B2 (zh) |
KR (1) | KR101941420B1 (zh) |
CN (1) | CN103702994B (zh) |
ES (1) | ES2576298T3 (zh) |
HK (1) | HK1194365A1 (zh) |
TW (1) | TWI554515B (zh) |
WO (1) | WO2012177707A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109725101A (zh) * | 2017-10-31 | 2019-05-07 | 正大天晴药业集团股份有限公司 | 盐酸特拉万星原料中有关物质的检测方法 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2663558A1 (en) * | 2011-01-14 | 2013-11-20 | Vertex Pharmaceuticals Incorporated | Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea |
AU2012205420B2 (en) * | 2011-01-14 | 2016-12-08 | Spero Therapeutics, Inc. | Process of making gyrase and topoisomerase IV inhibitors |
MX341342B (es) * | 2011-01-14 | 2016-08-17 | Vertex Pharma | Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea. |
KR101897952B1 (ko) * | 2011-01-14 | 2018-09-12 | 스페로 트리넴, 인코포레이티드 | 피리미딘 자이라제 및 토포이소머라제 iv 억제제 |
KR101941420B1 (ko) * | 2011-06-20 | 2019-01-23 | 스페로 트리넴, 인코포레이티드 | 자이라제 및 토포이소머라제 억제제의 인산에스테르 |
WO2014015105A1 (en) * | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof |
US9572809B2 (en) | 2012-07-18 | 2017-02-21 | Spero Trinem, Inc. | Combination therapy to treat Mycobacterium diseases |
US20170007615A1 (en) | 2014-02-03 | 2017-01-12 | Biota Europe Ltd | Antibacterial Compounds |
BR112017006669B1 (pt) | 2014-10-03 | 2023-04-18 | Ucb Biopharma Sprl | Derivados de imidazol pentacíclico fundido, composição farmacêutica compreendendo os mesmos e uso dos mesmos |
AU2016252885B2 (en) * | 2015-04-22 | 2021-05-20 | Matinas Biopharma Nanotechnologies, Inc. | Compositions and methods for treating mycobacteria infections and lung disease |
BR112018069937A2 (pt) | 2016-04-01 | 2019-02-05 | Sanofi Sa | derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf |
CN109219608B (zh) | 2016-04-01 | 2021-12-21 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合五环咪唑衍生物 |
US10654861B2 (en) | 2016-04-01 | 2020-05-19 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of TNF activity |
CN109195969B (zh) | 2016-04-01 | 2021-12-21 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合五环咪唑衍生物 |
CA3055863A1 (en) | 2017-03-15 | 2018-09-20 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
US11793754B1 (en) | 2022-06-16 | 2023-10-24 | King Abdulaziz University | Sodium hypochlorite and chlorhexidine based nanoemulsions and a method of preparation thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060025424A1 (en) * | 2003-01-31 | 2006-02-02 | Paul Charifson | Gyrase inhibitors and uses thereof |
WO2006022773A1 (en) * | 2004-07-29 | 2006-03-02 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2015676A1 (de) | 1970-04-02 | 1971-10-21 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Neue Imine der 2-Formyl-chinoxalindi-N-oxidcarbon-säure-(3) und deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als antimikrobielle Mittel |
US4174400A (en) | 1978-09-13 | 1979-11-13 | Merck & Co., Inc. | Anthelmintic benzimidazoles |
US4512998A (en) | 1980-10-20 | 1985-04-23 | Schering Corporation | Anthelmintic benzimidazole carbamates |
CA2028530A1 (en) | 1989-11-21 | 1991-05-22 | Christian Hubschwerlen | Substituted pyrimidobenzimidazole derivatives |
CA2172245C (en) | 1993-09-22 | 2003-04-08 | Jonathan Cohen | Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein |
JPH09508359A (ja) | 1994-01-14 | 1997-08-26 | ゾーマ コーポレイション | 抗グラム陽性細菌学的方法および物質 |
DE19514313A1 (de) | 1994-08-03 | 1996-02-08 | Bayer Ag | Benzoxazolyl- und Benzothiazolyloxazolidinone |
HRP960159A2 (en) | 1995-04-21 | 1997-08-31 | Bayer Ag | Benzocyclopentane oxazolidinones containing heteroatoms |
US5643935A (en) | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
TW538046B (en) | 1998-01-08 | 2003-06-21 | Hoechst Marion Roussel Inc | Aromatic amides having antiobiotic activities and the preparation processes, intermediates and pharmaceutical composition thereof |
AUPP873799A0 (en) | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
US6156373A (en) | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
GB9911594D0 (en) | 1999-05-19 | 1999-07-21 | Smithkline Beecham Plc | Novel compounds |
GB9912413D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US7419678B2 (en) | 2000-05-12 | 2008-09-02 | Cordis Corporation | Coated medical devices for the prevention and treatment of vascular disease |
US20040018228A1 (en) | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
MXPA03005298A (es) | 2000-12-15 | 2003-10-06 | Vertex Pharma | Inhibidores de girasa y usos de los mismos. |
US20030229390A1 (en) | 2001-09-17 | 2003-12-11 | Control Delivery Systems, Inc. | On-stent delivery of pyrimidines and purine analogs |
PL374315A1 (en) | 2001-10-25 | 2005-10-03 | Wisconsin Alumni Research Foundation | Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same |
US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US20030204168A1 (en) | 2002-04-30 | 2003-10-30 | Gjalt Bosma | Coated vascular devices |
PL374191A1 (en) | 2002-06-13 | 2005-10-03 | Vertex Pharmaceuticals Incorporated | 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections |
US8193352B2 (en) | 2003-01-31 | 2012-06-05 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
US7582641B2 (en) | 2003-01-31 | 2009-09-01 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
US8404852B2 (en) | 2003-01-31 | 2013-03-26 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
EP1948635A1 (en) | 2005-11-07 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Benzimidazole derivatives as gyrase inhibitors |
GB0612428D0 (en) | 2006-06-22 | 2006-08-02 | Prolysis Ltd | Antibacterial agents |
GB0724349D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Antibacterial agents |
US8481544B2 (en) | 2006-06-22 | 2013-07-09 | Biota Europe Limited | Antibacterial compositions |
RU2469034C2 (ru) | 2006-12-04 | 2012-12-10 | Астразенека Аб | Химические соединения |
GB0724342D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Anitbacterial compositions |
AU2009254928A1 (en) * | 2008-06-04 | 2009-12-10 | Astrazeneca Ab | Thiazolo [5, 4-B] pyridine and oxazolo [5, 4-B] pyridine derivatives as antibacterial agents |
US20110166088A1 (en) | 2008-06-25 | 2011-07-07 | Ranbaxy Laboratories Limited | Benzothiazoles and aza-analogues thereof use as antibacterial agents |
WO2011032050A2 (en) | 2009-09-11 | 2011-03-17 | Trius Therapeutics, Inc. | Gyrase inhibitors |
CN102725274A (zh) | 2009-10-16 | 2012-10-10 | Rib-X制药公司 | 抗微生物化合物和其制备和使用方法 |
US9181234B2 (en) | 2010-10-08 | 2015-11-10 | Biota Europe Ltd. | Antibacterial compounds |
AU2012205420B2 (en) * | 2011-01-14 | 2016-12-08 | Spero Therapeutics, Inc. | Process of making gyrase and topoisomerase IV inhibitors |
MX341342B (es) * | 2011-01-14 | 2016-08-17 | Vertex Pharma | Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea. |
EP2663558A1 (en) * | 2011-01-14 | 2013-11-20 | Vertex Pharmaceuticals Incorporated | Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea |
KR101897952B1 (ko) * | 2011-01-14 | 2018-09-12 | 스페로 트리넴, 인코포레이티드 | 피리미딘 자이라제 및 토포이소머라제 iv 억제제 |
KR101941420B1 (ko) * | 2011-06-20 | 2019-01-23 | 스페로 트리넴, 인코포레이티드 | 자이라제 및 토포이소머라제 억제제의 인산에스테르 |
US9604976B2 (en) | 2012-03-22 | 2017-03-28 | Spero Gyrase, Inc. | Antibacterial compounds |
WO2014015105A1 (en) * | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof |
US9572809B2 (en) * | 2012-07-18 | 2017-02-21 | Spero Trinem, Inc. | Combination therapy to treat Mycobacterium diseases |
-
2012
- 2012-06-20 KR KR1020147001427A patent/KR101941420B1/ko active IP Right Grant
- 2012-06-20 US US13/527,832 patent/US9125922B2/en active Active
- 2012-06-20 WO PCT/US2012/043266 patent/WO2012177707A1/en active Application Filing
- 2012-06-20 EP EP12731853.3A patent/EP2721026B1/en active Active
- 2012-06-20 TW TW101122096A patent/TWI554515B/zh active
- 2012-06-20 ES ES12731853.3T patent/ES2576298T3/es active Active
- 2012-06-20 JP JP2014517110A patent/JP5977344B2/ja active Active
- 2012-06-20 CN CN201280036458.1A patent/CN103702994B/zh active Active
-
2014
- 2014-07-30 HK HK14107773.2A patent/HK1194365A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060025424A1 (en) * | 2003-01-31 | 2006-02-02 | Paul Charifson | Gyrase inhibitors and uses thereof |
WO2006022773A1 (en) * | 2004-07-29 | 2006-03-02 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109725101A (zh) * | 2017-10-31 | 2019-05-07 | 正大天晴药业集团股份有限公司 | 盐酸特拉万星原料中有关物质的检测方法 |
CN109725101B (zh) * | 2017-10-31 | 2021-11-19 | 正大天晴药业集团股份有限公司 | 盐酸特拉万星原料中有关物质的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2721026B1 (en) | 2016-03-02 |
US9125922B2 (en) | 2015-09-08 |
ES2576298T3 (es) | 2016-07-06 |
TW201313732A (zh) | 2013-04-01 |
CN103702994B (zh) | 2016-03-23 |
JP2014520152A (ja) | 2014-08-21 |
TWI554515B (zh) | 2016-10-21 |
WO2012177707A1 (en) | 2012-12-27 |
US20130157979A1 (en) | 2013-06-20 |
KR20140041768A (ko) | 2014-04-04 |
HK1194365A1 (zh) | 2014-10-17 |
EP2721026A1 (en) | 2014-04-23 |
KR101941420B1 (ko) | 2019-01-23 |
JP5977344B2 (ja) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103702994B (zh) | 旋转酶和拓扑异构酶抑制剂的磷酸酯 | |
CA2824516C (en) | Pyrimidine gyrase and topoisomerase iv inhibitors | |
TWI595002B (zh) | (R)-2-(5-(2-(3-乙基脲基)-6-氟-7-(四氫呋喃-2-基)-1H-苯并[d]咪唑-5-基)嘧啶-2-基)丙烷-2-基磷酸二氫鹽之固體形式及其鹽 | |
KR101900249B1 (ko) | 자이라제 억제제 (r)1에틸3[6플루오로5[2(1하이드록시1메틸에틸)피리미딘5일]7(테트라하이드로푸란2일)1h벤즈이미다졸2일]우레아의 고체 형태 | |
KR101897950B1 (ko) | 자이라제 억제제 (r)1에틸3[5[2{1하이드록시1메틸에틸}피리미딘5일]7(테트라하이드로푸란2일}1h벤즈이미다졸2일]우레아의 고체 형태 | |
NZ612961B2 (en) | Pyrimidine gyrase and topoisomerase iv inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1194365 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170118 Address after: Massachusetts USA Patentee after: Sparrow, Tom blowing Address before: Massachusetts USA Patentee before: Vertex Pharmaceuticals Incorporated |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1194365 Country of ref document: HK |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200108 Address after: Massachusetts USA Patentee after: Sparrow therapy Address before: Massachusetts USA Patentee before: Sparrow, Tom blowing |
|
TR01 | Transfer of patent right |